Just stick it on and voil: appetite control and weight loss without the pain, logistics, or anxiety of a weekly needle
(Source: Truveta, May 2026) Important limitation from the researchers themselves: This analysis covered only semaglutide and tirzepatide, and did not account for other common PCOS treatments such as metformin, combined oral contraceptives, or anti-androgen therapies
[1] [2] Common adverse effects include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation, which typically diminish with continued use
Most clinicians expect it to be somewhere between the Phase 2 and TRIUMPH-4 numbers when full results arrive in summer 2026
However, several indirect considerations are relevant